Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Nephros, Inc.
  6. News
  7. Summary
    NEPH   US6406714005

NEPHROS, INC.

(NEPH)
  Report
Delayed Nasdaq  -  03:53 2022-12-08 pm EST
1.061 USD   +3.04%
11/21Nephros : UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K
PU
11/21Nephros Inc : Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K)
AQ
11/15NEPHROS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NEPHROS INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)

07/12/2021 | 10:32am EST

Item 1.01 Entry into a Material Definitive Agreement.

On July 9, 2021, Nephros, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Agreement") with GenArraytion, Inc., a Delaware corporation ("GenArraytion") and the shareholder of GenArraytion. Pursuant to the terms of the Agreement, the Company acquired substantially all of the assets of GenArraytion.

At closing, the Company issued 123,981 shares of Company common stock, par value $0.001 per share, to GenArraytion, reflecting an aggregate purchase price of $1.2 million. Fifty percent of these shares were issued without a risk of forfeiture and the remaining fifty percent of the shares are subject to a risk of forfeiture. This risk of forfeiture will lapse upon the satisfactory completion of certain intellectual property transition services. The Company will also make royalty payments to GenArraytion based on net sales of GenArraytion products over the next five years and has agreed to file a registration statement covering the shares issued to GenArraytion within sixty days from the date of the Agreement.

The Agreement contains customary representations and warranties by GenArraytion. Additionally, GenArraytion agreed to customary indemnification obligations to the Company over the one-year period ending July 9, 2022, subject to certain limitations as set forth in the Agreement.

The foregoing summary of the Agreement is qualified in its entirety by reference to the complete Agreement, a copy of which will be filed with the Company's Form 10-Q for the quarter ended September 30, 2021.

A copy of the press release announcing the acquisition is filed herewith as Exhibit 99.1.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 above regarding the issuance of shares to GenArraytion is incorporated herein by reference. The issuance of shares to GenArraytion was made in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D thereunder.

Item 9.01. Financial Statements and Exhibits.



(d)           Exhibits

Exhibit No.   Description
   99.1         Nephros, Inc. Press Release, dated July 12, 2021.

© Edgar Online, source Glimpses

All news about NEPHROS, INC.
11/21Nephros : UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K
PU
11/21Nephros Inc : Completion of Acquisition or Disposition of Assets, Financial Statements and..
AQ
11/15NEPHROS INC Management's Discussion and Analysis of Financial Condition and Results of..
AQ
11/15Blue Water Solutions, Inc. completed the acquisition of Pathogen Detection Systems line..
CI
11/02Transcript : Nephros, Inc., Q3 2022 Earnings Call, Nov 02, 2022
CI
11/02Nephros Announces Results for Quarter Ended September 30, 2022
AQ
11/02Nephros, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022
CI
10/19B. Riley Securities Lowers Nephros' Price Target to $4.25 from $5.25 Ahead of Q3 Result..
MT
10/19Nephros Third Quarter 2022 Financial Results Conference Call
AQ
10/12Nephros to Present at LD Micro Main Event XV
NE
More news
Analyst Recommendations on NEPHROS, INC.
More recommendations
Financials (USD)
Sales 2022 10,3 M - -
Net income 2022 -7,13 M - -
Net cash 2022 3,72 M - -
P/E ratio 2022 -1,64x
Yield 2022 -
Capitalization 10,6 M 10,6 M -
EV / Sales 2022 0,67x
EV / Sales 2023 0,58x
Nbr of Employees 34
Free-Float 89,9%
Chart NEPHROS, INC.
Duration : Period :
Nephros, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,03 $
Average target price 3,63 $
Spread / Average Target 252%
EPS Revisions
Managers and Directors
Andrew Astor President, Chief Executive Officer, CFO & Director
Michael Milman Vice President-Research & Development
Oliver Spandow Independent Director
Alisa Lask Independent Director
Thomas Gwydir Independent Director
Sector and Competitors